GPC3 and cancer: Studies have shown that any protein with either an arginine-rich domain or a protein transduction domain (PTD) will bind the heparan sulphate proteoglycan on a cell surface, resulting in a non-specific binding of native or wild type HBc particles to any cells including cancer cells [35], [36], [37].